Early work revealed that TFEB is highly effective in ameliorating tau/NFT pathology and rescuing cognitive impairment and neurodegeneration. TFEB targets only the aberrant tau species and this ...

Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

Activated p53 negatively regulates mTORC1 signaling, which is one of the major kinases responsible for the phosphorylation of TFEB and TFE3. The autophagy-lysosomal pathway is activated via the ...